Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 2/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771661 | 0.84 | DHODH (0.55) | — | |
| SCHEMBL5460433 | 0.83 | PARP1 (0.57) | — | |
| SCHEMBL5463373 | 0.75 | PARP1 (0.64) | PKN1PKN2 | |
| SCHEMBL23835770 | 0.74 | PARP1 (0.51) | PKN1PKN2CDK1RETKDR | |
| SCHEMBL16674516 | 0.71 | PARP1 (0.55) | PKN1PKN2CDK1RETKDR | |
| SCHEMBL1170810 | 0.66 | PKN1 (0.77) | PKN1PKN2 | |
| SCHEMBL26177802 | 0.66 | PARP1 (0.59) | — | |
| SCHEMBL5454668 | 0.65 | PARP1 (0.55) | — | |
| SCHEMBL5456641 | 0.65 | PARP1 (0.55) | — | |
| SCHEMBL7649222 | 0.65 | PKN1 (0.67) | PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | claimed |
| EP-1622893-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | Hideg, Kalman (HU) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096793-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | HIDEG KALMAN (HU) | 2004-11-11 | — | — | WO | claimed |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | PKN1 672/4885PKN2 630/4885CDK1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.